Table 4 Univariate and multivariate COX regression analysis identified clinical factors associated with prognosis
Variables | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
HR | 95%CI of HR | P value | HR | 95%CI of HR | P value | |
TCGA training datasets | ||||||
 14-IRGPs signature | ||||||
  Risk score (High/Low) | 2.97 | 1.99–4.43 | 7.79E-08 | 2.53 | 1.54–4.13 | 0.0002 |
  Age | 1.02 | 1.01–1.04 | 0.009 | 1.02 | 0.99–1.04 | 0.0550 |
  Gender (Male vs Female) | 0.70 | 0.47–1.04 | 0.077 | 0.94 | 0.56–1.5 | 0.8236 |
  T3/T4 vs T1/T2 | 0.97 | 0.66–1.43 | 0.895 | 0.43 | 0.24–0.74 | 0.0025 |
  N1/N2/N3 VS N0 | 1.21 | 0.78–1.85 | 0.39 | 1.00 | 0.59–1.68 | 0.9985 |
  Stage IV vs Stage I/ II/III | 1.97 | 1.31–2.95 | 0.001 | 2.65 | 1.46–4.78 | 0.0012 |
  G3/G4 vs G1/G2 | 1.16 | 0.76–1.77 | 0.491 | 0.94 | 0.57–1.52 | 0.7969 |
  Smoking vs Non-smoking | 0.95 | 0.59–1.52 | 8.35E-01 | 0.85 | 0.48–1.49 | 0.5707 |
TCGA validation datasets | ||||||
 14-IRGPs signature | ||||||
  Risk score (High/Low) | 1.96 | 1.32–2.91 | 7.93E-04 | 1.72 | 1.12–2.62 | 0.0123 |
  Age | 1.02 | 0.99–1.04 | 0.064 | 1.02 | 0.99–1.03 | 0.1549 |
  Gender (Male vs Female) | 0.77 | 0.51–1.17 | 0.223 | 0.79 | 0.47–1.31 | 0.3577 |
  T3/T4 vs T1/T2 | 1.75 | 1.13–2.71 | 0.011 | 2.05 | 1.17–3.59 | 0.0120 |
  N1/N2/N3 VS N0 | 1.29 | 0.87–1.91 | 0.209 | 1.39 | 0.86–2.23 | 0.1674 |
  Stage IV vs Stage I/ II/III | 1.36 | 0.90–2.05 | 0.142 | 0.87 | 0.49–1.53 | 0.6379 |
  G3/G4 vs G1/G2 | 1.22 | 0.77–1.93 | 0.393 | 1.20 | 0.74–1.93 | 0.4439 |
  Smoking vs Non-smoking | 1.33 | 0.82–2.15 | 0.247 | 1.34 | 0.77–2.31 | 0.2987 |
TCGA entire datasets | ||||||
 14-IRGPs signature | ||||||
  Risk score (High/Low) | 2.54 | 1.92–3.35 | 6.51E-11 | 2.01 | 1.41–2.84 | 9.36E-05 |
  Age | 1.02 | 1.01–1.03 | 0.0013 | 1.02 | 1.01–1.04 | 0.0087 |
  Gender (Male vs Female) | 0.74 | 0.55–0.97 | 0.034 | 0.97 | 0.66–1.41 | 0.8830 |
  T3/T4 vs T1/T2 | 1.28 | 0.96–1.70 | 0.093 | 0.72 | 0.47–1.09 | 0.1107 |
  N1/N2/N3 VS N0 | 1.20 | 0.87–1.66 | 0.271 | 1.07 | 0.73–1.54 | 0.7276 |
  Stage IV vs Stage I/ II/III | 1.65 | 1.24–2.20 | 6.20E-04 | 1.85 | 1.21–2.82 | 0.0046 |
  G3/G4 vs G1/G2 | 1.15 | 0.84–1.57 | 0.365 | 0.83 | 0.58–1.18 | 0.3067 |
  Smoking vs Non-smoking | 1.14 | 0.81–1.59 | 0.45 | 1.07 | 0.7–1.63 | 0.7539 |
GSE65858 | ||||||
 14-IRGPs signature | ||||||
  Risk score (High/Low) | 1.94 | 1.27–2.97 | 0.0021 | 1.90 | 1.23–2.92 | 0.0035 |
  Age | 1.03 | 1.01–1.05 | 0.0130 | 1.04 | 1.01–1.06 | 0.0036 |
  Gender (Male vs Female) | 1.05 | 0.62–1.77 | 0.8680 | 1.06 | 0.62–1.82 | 0.8378 |
  T3/T4 vs T1/T2 | 2.92 | 1.81–4.72 | 1.23E-05 | 2.16 | 1.26–3.69 | 0.0049 |
  N1/N2/N3 VS N0 | 2.14 | 1.38–3.32 | 0.0007 | 1.39 | 0.73–2.65 | 0.3216 |
  Stage IV vs Stage I/ II/III | 2.92 | 1.72–4.95 | 7.22E-05 | 1.55 | 0.68–3.55 | 0.2987 |
  Smoking vs Non-smoking | 0.94 | 0.55–1.59 | 0.8210 | 1.14 | 0.64–2.03 | 0.6493 |